Status quo of current clinical drug regimens for small cell lung cancer and new progress in the potential target drug therapeutic regimens
- VernacularTitle:小细胞肺癌的临床用药方案现状及潜在靶点药物治疗方案新进展
- Author:
Huanqi ZHANG
1
;
Xu LIN
2
;
Shuying SHEN
3
;
Yangling LI
1
Author Information
1. College of Pharmaceutical Sciences/Research Center for Clinical Pharmacy，Zhejiang University，Hangzhou 310006，China
2. Dept. of Thoracic Surgery，the First Affiliated Hospital，Zhejiang University School of Medicine，Hangzhou 310006，China
3. Dept. of Clinical Pharmacology/Zhejiang Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research，the Affiliated Hangzhou First People’s Hospital，Zhejiang University School of Medicine，Hangzhou 310006，China
- Publication Type:Journal Article
- Keywords:
small cell lung cancer;
chemotherapy;
immunotherapy;
therapeutic targets;
potential target drug therapeutic options
- From:
China Pharmacy
2023;34(16):2039-2043
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer （SCLC） accounts for about 15% in lung cancer and is highly malignant， heterogeneous and invasive. Etoposide combined with platinum-based chemotherapy is the basis of standard first-line treatment for extensive-stage SCLC， but suffers from the problem of susceptibility to drug resistance and relapse. In recent years， the emergence of new immunological drugs and novel cytotoxic drugs has improved the survival of SCLC patients to a certain extent， especially bringing therapeutic hope to patients with relapsed/refractory SCLC. In this paper， we review the current clinical drug regimens and the new progress of potential target drug therapeutic regimens for the treatment of SCLC. At present， the first-， second- and third-line schemes of SCLC include etoposide+carboplatin， atezolizumab+etoposide+platinum， adebrelimab， topotecan， docetaxel， etc.； the current drug targets for the treatment of SCLC mainly focus on topoisomerase Ⅱ/Ⅰ， DNA， the immune checkpoint molecules programmed death-1/programmed death-ligand 1， tubulin， etc. The potential target drug therapeutic options include alisertib+ paclitaxel， rovalpituzumab， APG-1252， etc.， and mainly focus on DNA damage response pathways and immune pathways， which can achieve the prolongation of patient survival by exerting anti-tumor effects through aurora kinase A and other potential targets.
